Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Avidity Biosciences Inc (RNA)

Avidity Biosciences Inc (RNA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,812,013
  • Shares Outstanding, K 79,719
  • Annual Sales, $ 9,560 K
  • Annual Income, $ -212,220 K
  • 60-Month Beta 0.78
  • Price/Sales 192.13
  • Price/Cash Flow N/A
  • Price/Book 3.41
Trade RNA with:

Options Overview Details

View History
  • Implied Volatility 97.33% ( +6.95%)
  • Historical Volatility 62.39%
  • IV Percentile 75%
  • IV Rank 47.98%
  • IV High 161.97% on 11/16/23
  • IV Low 37.71% on 08/18/23
  • Put/Call Vol Ratio 0.45
  • Today's Volume 1,932
  • Volume Avg (30-Day) 675
  • Put/Call OI Ratio 0.43
  • Today's Open Interest 2,568
  • Open Int (30-Day) 6,413

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.81
  • Number of Estimates 3
  • High Estimate -0.70
  • Low Estimate -0.95
  • Prior Year -0.74
  • Growth Rate Est. (year over year) -9.46%

Price Performance

See More
Period Period Low Period High Performance
1-Month
21.56 +12.06%
on 04/04/24
27.66 -12.65%
on 04/03/24
+0.46 (+1.94%)
since 03/22/24
3-Month
9.93 +143.21%
on 01/23/24
27.66 -12.65%
on 04/03/24
+13.79 (+132.98%)
since 01/22/24
52-Week
4.82 +400.73%
on 10/31/23
27.66 -12.65%
on 04/03/24
+7.84 (+48.04%)
since 04/21/23

Most Recent Stories

More News
Avidity Biosciences Announces New Positive AOC 1001 Data Demonstrating Improvement in Multiple Additional Functional Endpoints and Favorable Long-term Safety and Tolerability in People with Myotonic Dystrophy Type 1

New AOC 1001 data demonstrate improvement in additional functional measures including hand grip, muscle strength and patient reported outcomes, augmenting...

RNA : 24.16 (+6.29%)
Avidity Biosciences to Participate in Upcoming Investor Conferences

/PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...

RNA : 24.16 (+6.29%)
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...

RNA : 24.16 (+6.29%)
Wave of FDA Fast Track Designations Highlight Biotech Momentum Carrying into 2023

FN Media Group Presents USA News Group News Commentary   Vancouver, BC – September 13, 2023 – USA News Group  –  Sufferers of many different ailments saw reason to grow their hope in 2022 when...

ONCY : 1.0400 (-1.89%)
ONC.TO : 1.46 (+1.39%)
FULC : 7.25 (+5.99%)
RNA : 24.16 (+6.29%)
BCTX : 2.20 (+8.91%)
BCT.TO : 2.94 (+2.80%)
GILD : 66.95 (+0.28%)
Avidity Biosciences Joins with Patient Communities to Raise Awareness During National Muscular Dystrophy Awareness Month as it Advances Three Muscular Dystrophy Clinical Programs

Avidity supports World Duchenne Awareness Day, International Myotonic Dystrophy Awareness Day, FSHD Society Walk & Roll to Cure FSHD and Global Genes Week in...

RNA : 24.16 (+6.29%)
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...

RNA : 24.16 (+6.29%)
Avidity Biosciences Receives FDA Orphan Drug Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy in People with Mutations Amenable to Exon 44 Skipping

/PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...

RNA : 24.16 (+6.29%)
Avidity Biosciences Reports Second Quarter 2023 Financial Results and Recent Highlights

/PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...

RNA : 24.16 (+6.29%)
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...

RNA : 24.16 (+6.29%)
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...

RNA : 24.16 (+6.29%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Avidity Biosciences Inc. is a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates(TM). The company's AOC platform design, engineer and develop therapeutics which combine the tissue selectivity of monoclonal antibodies and the...

See More

Key Turning Points

3rd Resistance Point 27.15
2nd Resistance Point 25.99
1st Resistance Point 25.07
Last Price 24.16
1st Support Level 23.00
2nd Support Level 21.84
3rd Support Level 20.92

See More

52-Week High 27.66
Last Price 24.16
Fibonacci 61.8% 18.94
Fibonacci 50% 16.24
Fibonacci 38.2% 13.55
52-Week Low 4.82

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar